medigraphic.com
Instituto Nacional de Salud Pública

2016, Número 2

<< Anterior Siguiente >>

salud publica mex 2016; 58 (2)


Panorama epidemiológico, avances diagnósticos, prevención, tratamiento y manejo de cáncer ovárico epitelial en México

Gallardo-Rincón D, Espinosa-Romero R, Rosemary MW, Mendoza-Martínez R, del Villar-Álvarez S, Oñate-Ocaña L, Isla-Ortiz D, Márquez-Manríquez JP, Apodaca-Cruz Á, Meneses-García A

Idioma: Ingles.
Referencias bibliográficas: 45
Paginas: 302-308
Archivo PDF: 221.61 Kb.


RESUMEN

El cáncer ovárico epitelial (COE) ha sido subdiagnosticado debido a que no tiene presentación clínica específica y a que los signos y síntomas son similares al síndrome de colon irritable y a la enfermedad inflamatoria pélvica. Es menos común que el cáncer de mama o el cervicouterino, pero es más letal. En general, tiene diseminación temprana a cavidad peritoneal, lo cual retrasa un pronóstico oportuno e incrementa la tasa de diagnóstico de enfermedad avanzada. Usualmente, el diagnóstico sorprende a la mujer y al médico de primer contacto. Entonces, es necesario contar con programas de prevención y diagnóstico temprano. El COE tiene 80% de respuesta quirúrgica, pero cerca de 70% de las pacientes puede recaer en cinco años. Los objetivos de este documento son presentar un resumen de la epidemiología del COE y comentar los avances en prevención, diagnóstico y tratamiento de este cáncer. Esto despertará la conciencia acerca de la importancia de esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Cancer Society. Global Cancer Fact & Figures 2011 (2nd Ed.). Atlanta: American Cancer Society, 2011.

  2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.

  3. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012;460(3):237-249.

  4. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.

  5. World Health Organization. Estimated cancer incidence, mortality and prevalence worldwide, Globocan 2012 [internet site]. Lyon: Globocan, 2016. Available at: http://globocan.iarc.fr/Default.aspx

  6. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in woman presenting to primary care. JAMA 2004;291:2705-2712.

  7. Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer. Obstet Gynecol 2001;98:212-217.

  8. Goff BA, Mandel LS, Muntz HG Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-2075.

  9. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011;117:742-746.

  10. Chan JK, Kapp DS, Shin JY, Husain A, Teng NN, Berek JS, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007;109:1342-1350.

  11. Clarke-Pearson DL. Screening for Ovarian Cancer. N Engl J Med 2009;361:170-177.

  12. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al. Statement in risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-162.

  13. Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006;15(2):359-363.

  14. Bristow RE, Karlan BY Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996;66(4):499-507.

  15. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynecological cancer: a systematic review. Reprod Biomed Online 2009;19:398-405.

  16. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-394.

  17. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385:1835-1842.

  18. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006;103:1122-1129.

  19. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007;166:894-901.

  20. Beral V, Doll R, Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-314.

  21. Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the Agency for Healthcare Research and Quality’s evidence report on breastfeeding in developed countries. Breastfeed Med 2009; 4 Suppl 1:S17-S30.

  22. Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum Reprod Update 2011;17:55-67.

  23. Hanna L. Prevention of ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 2016;(30):1-12.

  24. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, el at. Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305(22):2295-2230.

  25. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al.A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18(3):414-420.

  26. van Nagell JR Jr, Higgins RV, Donaldson ES, Gallion HH, Powell DE, Pavlik EJ, et al. Transvaginal sonography as a screening method for ovarian cancer. Cancer 1990; 65(Issue 3):573-577.

  27. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;(192):1214-1222.

  28. Rosenthal AN. Ovarian Cancer Screening in the High Risk population –the UK Familial Ovarian ancer Screening Study (UKFOCSS). Int J Gynecol Cancer 2012;(22):S27-S28.

  29. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-7926.

  30. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology 2009;10(4):327-340.

  31. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 2013;119(19):3454-3461.

  32. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Nat Cancer Inst 2010;102(4):222-229.

  33. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008 Apr; 27(2):151-160.

  34. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Ovarian Cancer 2009 [internet document]. Washington: NCNN, 2015. Available at: http://www.nccn.org/professionals/physician_gls/f_ guidelines.asp

  35. Jonathan S. Berek, Christopher Crumb, Michael Friedlander. FIGO Cancer Report 2012, Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 2012;119S2:S118-S129.

  36. American Joint Committee on Cancer. 8th Edition by the Numbers [internet document]. Chicago: AJCC, 2016.: Available from: https://cancerstaging. org/About/Pages/8th-Edition.aspx

  37. American Joint Committee on Cancer. Cancer Staging Manual, 7th Ed. New York: Springer, 2009.

  38. Vergote I, Tropé CG, Kristensen GB, Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer, N Engl J Med 2010;363:943-953.

  39. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al, Staging Laparotomy in Early Ovarian Cancer. JAMA 1983;250(22):3072-3076.

  40. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer Inter Group. J Clin Oncol 2009; 27(9):1419-1425.

  41. Gallardo-Rincón D, Cantú-de-León D, Alanís-López P, Alvarez-Avitia MA, Bañuelos-Flores J, Herbert-Núñez GS, et al. Tercer Consenso Nacional de Cáncer de Ovario 2011. Grupo de Investigación de Cáncer de Ovario y Tumores Ginecológicos en México “GICOM”. Rev Inv Clin 2011;63(6):665-702.

  42. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer a phase 3, open-label, randomized controlled trial. Lancet 2009;374: 1331-1338.

  43. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. Phase 3 Trial of Bevacizumab in ovarian cancer, ICON 7 study. N Engl J Med 2011;365:2484-2496.

  44. Ledermann J, Harter P, Gourley CH. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N Engl J Med 2012;366:1382-1392.

  45. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi24-32.6:vi24-vi32.




2020     |     www.medigraphic.com